Scarica l'app Stockscreener
92.00
6.24%
5.40
Dopo l'orario di chiusura:
91.99
-0.01
-0.01%
Precedente Chiudi:
$86.60
Aprire:
$83.04
Volume 24 ore:
1.33M
Relative Volume:
0.87
Capitalizzazione di mercato:
$4.49B
Reddito:
-
Utile/perdita netta:
$-192.89M
Rapporto P/E:
-23.60
EPS:
-3.8976
Flusso di cassa netto:
$-172.97M
1 W Prestazione:
-0.84%
1M Prestazione:
-17.15%
6M Prestazione:
-11.97%
1 anno Prestazione:
+77.30%
Intervallo 1D:
$83.04
$95.56
Intervallo di 1 settimana:
$83.04
$95.56
Portata 52W:
$44.42
$151.02
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
92.00 | 4.49B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-12 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen - marketbeat.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Needham cuts Celcuity stock price target on updated revenue model By Investing.com - Investing.com Australia
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - marketbeat.com
H.C. Wainwright Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Celcuity (CELC) Q2 2026 Ergebniskonferenz: REVTORPYK-Markteinführung für Ende Q3 geplant - TradingKey
Celcuity's (CELC) "Buy" Rating Reaffirmed at HC Wainwright - marketbeat.com
Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings - marketbeat.com
Celcuity remains a Buy as FDA approval and stro... - Pluang
Stifel cuts Celcuity stock price target on refined market model - Investing.com
Stifel cuts Celcuity stock price target on refined market model By Investing.com - Investing.com Australia
Celcuity (NASDAQ:CELC) Given New $140.00 Price Target at Needham & Company LLC - marketbeat.com
Celcuity: REVTORPYK Is Now A Commercial Story (NASDAQ:CELC) - Seeking Alpha
Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus - marketbeat.com
Celcuity Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Celcuity Analysts Slash Their Forecasts After Q2 Loss - Benzinga
Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside - TradingView
Needham cuts Celcuity stock price target on updated revenue model - Investing.com
Celcuity Inc. Stock 12‑Month Price Target Cut to $162.18, Implies 87% Upside - TradingView
Celcuity Q2 Net Loss Widens to $73.6M as R&D Spending Rises - minichart.com.sg
CELC SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
CELCUITY INC. : JEFFERIES RAISES TARGET PRICE TO $163 FROM $153 - moomoo.com
Celcuity Q2 Adjusted Loss Widens - moomoo.com
Celcuity Q2 2026 Earnings Call Transcript - marketbeat.com
CELC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Celcuity Inc. - ACCESS Newswire
CELCUITY INC. : NEEDHAM CUTS TARGET PRICE TO $140 FROM $157 - Bitget
Celcuity Q2 Earnings Call Highlights - marketbeat.com
CELCUITY ($CELC) Releases Q2 2026 Earnings - Quiver Quantitative
CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch - TradingView
Celcuity Inc. (CELC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celcuity Reports Q2 2026 Form 10-Q Highlighting FDA-Approved REVTORPYK and Ongoing Clinical Trials - Kalkine Media
Celcuity Q2 Results: Net Loss Widens To $78.9 Million Amid Launch Prep - scanx.trade
Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts - Stock Titan
Celcuity Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Celcuity beats second quarter loss estimates By Investing.com - Investing.com South Africa
Celcuity beats second quarter loss estimates - Investing.com
Celcuity posts narrower-than-expected loss as R&D costs decreased - TradingView
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12 - marketscreener.com
Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celcuity earnings loom as breast cancer drug approval fuels optimism By Investing.com - Investing.com Canada
Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
California State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC - marketbeat.com
Bank of America Corp DE Sells 262,789 Shares of Celcuity, Inc. $CELC - marketbeat.com
Assenagon Asset Management S.A. Buys New Shares in Celcuity, Inc. $CELC - marketbeat.com
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):